Almac And PHT Announce Formal Alliance To Improve Clinical Trial Data Quality
Main Category: Clinical Trials / Drug TrialsAlso Included In: IT / Internet / E-mail; Medical Devices / Diagnostics; Medical Students / Training
Article Date: 24 Apr 2009 - 3:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Almac Clinical Technologies and PHT Corporation announced a formal alliance to improve clinical trial productivity through a variety of education initiatives and data integration efforts that will reduce clinical trial site burdens while improving study data collection and reporting.
As part of their alliance activities, PHT and Almac have agreed to provide consultation with clinical trial sponsors on the difficult question of choosing the appropriate technology for studies involving electronic patient-reported outcomes (ePRO). Currently, sponsors face challenges relating to the choice of using either a handheld device or an interactive voice or Web response system to capture ePRO data in their trials. To help clients better understand this issue, PHT and Almac will offer joint consultation with clients upon request and conduct several workshops and panel sessions on this topic at industry events in 2009-10.
The first joint data initiative involves integration of Almac's patient screening and randomization data with PHT's handheld devices for ePRO studies. Sponsors who choose to work with both Almac and PHT will be afforded the opportunity to have real-time data feeds from Almac's industry-leading integrated IVR/IWR technology directly into PHT's market-leading handheld ePRO product suite, the LogPad® and SitePad™ Systems. Almac will send PHT real-time automated feeds whenever a patient is screened and randomized, improving data quality for sponsors and increasing clinical trial sites' productivity. The integration will remove the need for sites to manually enter in the same information provided by the Almac IVR system into the LogPad, thereby reducing data entry errors that can be costly to remediate. Future efforts will involve deeper data integration, including seamless integration between Almac's study data with that collected by PHT and EDC vendors. Both Almac and PHT's advanced technology offerings consistently integrate with other systems using CDISC standards.
Philip Lee, CEO of PHT, comments about the benefits that the alliance will provide to clients. "Our customers are constantly looking for ways to integrate multiple streams of eClinical data and reduce the data entry burden on sites. Our partnership with Almac offers added value for both sponsors and sites with one less data source to reconcile and the removal of a manual data entry step. Together, PHT and Almac are helping sponsors and sites remove time-consuming data cleaning tasks to focus on what they care about most -- the health and safety of patients and conducting rigorous scientific research."
Almac Clinical Technologies' President Jim Murphy believes that deeper integration of data between best-of-breed technology vendors offers tremendous benefits for sponsors. "Obtaining the highest quality data from vendors and sites is the primary need of pharmaceutical study sponsors. This alliance satisfies that need by integrating data from the highest quality clinical technology companies. The Almac/PHT alliance offers sponsors an opportunity to resist compromising data quality and trading off high quality technology or customer service to work with one vendor who offers all technologies for data collection, but is not best-of-breed in all or any of them."
PHT and Almac plan to launch their integrated offering by mid-2009. Further details about the alliance and joint initiatives are available by contacting either PHT or Almac Clinical Technologies.
Both Almac and PHT will be exhibiting at next week's Partnerships with CRO's Conference; come visit them for more information at Booth's 317 and 520.
Source
Almac Group
Visit our clinical trials / drug trials section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/147339.php>
APA
http://www.medicalnewstoday.com/releases/147339.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



